Form 4: ResMed CEO Michael Farrell Exercises Options and Sells Shares Under Pre-Arranged Plan
Insider Transaction Report
ResMed CEO Michael Farrell executed a pre-arranged transaction, exercising stock options and simultaneously selling an equal number of shares.
Summary
- Michael J. Farrell, Chief Executive Officer of ResMed Inc. (RMD), engaged in a pre-arranged transaction on July 7, 2025.
- He exercised options to acquire 8,009 shares of ResMed Common Stock at an exercise price of $101.64 per share.
- Concurrently, he sold 8,009 shares of ResMed Common Stock at a weighted average sale price of $256.7207 per share.
- The transactions were conducted under a Rule 10b5-1 plan adopted on October 31, 2024.
- Following these transactions, Michael J. Farrell beneficially owns 455,503 shares of ResMed Common Stock and 32,038 derivative securities (options).
Sentiment
Score: 7
Explanation: The transaction represents a routine, pre-planned exercise of options and sale of shares by the CEO, which is a profitable event for the executive and executed under a Rule 10b5-1 plan, mitigating concerns about opportunistic insider trading.
Positives
- The exercise price of $101.64 per share is significantly lower than the weighted average sale price of $256.7207 per share, indicating a profitable transaction for the CEO.
- The transactions were conducted under a Rule 10b5-1 plan, which indicates a pre-arranged trading strategy and helps mitigate concerns about opportunistic insider trading.
Negatives
- The sale of shares by a Chief Executive Officer, even under a pre-arranged plan, could be perceived by some investors as a reduction in direct ownership, though this is a common liquidity event for executives.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- The CEO, Michael J. Farrell, exercised stock options and sold shares of the company's common stock, which is a transaction between an insider and the company/market.
Stakeholder Impact
- Shareholders: The transaction is a routine liquidity event for the CEO, executed under a pre-arranged plan, which generally has a neutral to slightly positive impact as it demonstrates planned executive compensation realization rather than opportunistic selling.
Key Dates
| Date | Description |
|---|---|
| 11/11/2019 | Date options first became exercisable for the options that were exercised (options vest 1/3 per year). |
| 10/31/2024 | Date the Rule 10b5-1 plan was adopted. |
| 07/07/2025 | Date of the reported transactions (option exercise and share sale). |
| 07/08/2025 | Date the Form 4 was signed by the reporting person. |
| 11/14/2025 | Expiration date of the exercised options. |
Recommendation
holdKeywords
ResMed, RMD, Michael Farrell, CEO, Form 4, insider trading, stock options, share sale, 10b5-1 plan, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.